Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

BCAB BioAtla Inc

Price (delayed)

$0.4934

Market cap

$23.97M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.22

Enterprise value

-$7.84M

BioAtla® is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!™) platforms. ...

Highlights
BCAB's debt has shrunk by 71% YoY and by 34% QoQ
The company's EPS has surged by 51% YoY and by 15% QoQ
The equity has dropped by 99% year-on-year and by 96% since the previous quarter
BioAtla's quick ratio has shrunk by 52% YoY and by 40% QoQ

Key stats

What are the main financial stats of BCAB
Market
Shares outstanding
48.59M
Market cap
$23.97M
Enterprise value
-$7.84M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
52.68
Price to sales (P/S)
2.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.71
Earnings
Revenue
$11M
Gross profit
$11M
Operating income
-$67.1M
Net income
-$61.88M
EBIT
-$61.88M
EBITDA
-$61.01M
Free cash flow
-$57.4M
Per share
EPS
-$1.22
EPS diluted
-$1.22
Free cash flow per share
-$0.99
Book value per share
$0.01
Revenue per share
$0.19
TBVPS
$0.66
Balance sheet
Total assets
$38.29M
Total liabilities
$37.74M
Debt
$554,000
Equity
$547,000
Working capital
$21.53M
Liquidity
Debt to equity
1.01
Current ratio
2.35
Quick ratio
2.02
Net debt/EBITDA
0.52
Margins
EBITDA margin
-554.6%
Gross margin
100%
Net margin
-562.5%
Operating margin
-610%
Efficiency
Return on assets
-111.7%
Return on equity
-357.9%
Return on invested capital
N/A
Return on capital employed
-277.7%
Return on sales
-562.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BCAB stock price

How has the BioAtla stock price performed over time
Intraday
-5.62%
1 week
26.64%
1 month
-11.58%
1 year
-69.54%
YTD
-16.54%
QTD
42.27%

Financial performance

How have BioAtla's revenue and profit performed over time
Revenue
$11M
Gross profit
$11M
Operating income
-$67.1M
Net income
-$61.88M
Gross margin
100%
Net margin
-562.5%

BCAB financials

BioAtla's net income has increased by 48% YoY and by 11% QoQ
BCAB's operating income is up by 46% YoY and by 9% from the previous quarter
BCAB's net margin is up by 11% QoQ
The operating margin has increased by 9% since the previous quarter

Price vs fundamentals

How does BCAB's price correlate with its fundamentals

BCAB Price vs fundamentals

BCAB Earnings waterfall

BCAB Price vs fair value

Growth

What is BioAtla's growth rate over time

BCAB growth chart

Valuation

What is BioAtla stock price valuation
P/E
N/A
P/B
52.68
P/S
2.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.71

Valuation vs average

Price to earnings (P/E)

The company's EPS has surged by 51% YoY and by 15% QoQ

Price to book (P/B)

The equity has dropped by 99% year-on-year and by 96% since the previous quarter

Price to sales (P/S)

Efficiency

How efficient is BioAtla business performance
The company's return on equity has shrunk by 155% YoY and by 52% QoQ
BioAtla's ROA has decreased by 27% YoY and by 9% from the previous quarter
The company's return on sales rose by 11% QoQ

Dividends

What is BCAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCAB.

Financial health

How did BioAtla financials performed over time

Assets vs liabilities

The company's total assets has shrunk by 57% YoY and by 27% QoQ
BioAtla's quick ratio has shrunk by 52% YoY and by 40% QoQ

Debt vs equity

The equity has dropped by 99% year-on-year and by 96% since the previous quarter
BCAB's debt has shrunk by 71% YoY and by 34% QoQ

Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.